ArticleLeukemia2014
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 125 citations in OpenAlex.
- Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.Blood advances · 2022Trial
- A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.Leukemia · 2022Trial
- Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.Haematologica · 2017Trial
- Trial
- Amyloidosis and Thoracic Aortic Disease: A Scoping Review.Journal of clinical medicine · 2026Review
- Article
- Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update.Diagnostics (Basel, Switzerland) · 2024Review
- Multidisciplinary supportive care in systemic light chain amyloidosis.Blood research · 2022Review
- Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.PloS one · 2022Article
- Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis.Blood research · 2021Article
- Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis.Internal and emergency medicine · 2021Article
- AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies:JACC. CardioOncology · 2021Review
- Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.ESC heart failure · 2021Review
- Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021Review
- Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.Circulation research · 2021Review
- Current Challenges of Cardiac Amyloidosis Awareness among Romanian Cardiologists.Diagnostics (Basel, Switzerland) · 2021Article
- Recent advances in the diagnosis and management of amyloid cardiomyopathy.Faculty reviews · 2021Review
- Light-chain amyloid myopathy isolated to skeletal muscles: A case report.Clinical case reports · 2020Article
- Amyloid cardiomyopathy.Herz · 2020Review
- Systemic amyloidosis: moving into the spotlight.Leukemia · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral melphalan and dexamethasone (MDex) is a standard treatment for patients with AL amyloidosis who are not eligible for stem cell transplantation at many referral centers. However, following encouraging reports on the activity of bortezomib combined with alkylators and dexamethasone, these combinations are being moved to frontline therapy. We compared the outcome of 87 patients treated with bortezomib plus MDex (BMDex) with that of 87 controls treated with MDex. Patients and controls were matched for age, cardiac and renal function and free light chain burden. A higher rate of complete responses was observed with BMDex (42 vs 19%), but this did not result in a survival improvement in the overall population. However, a significant survival advantage for BMDex was observed in patients without severe (New York Heart Association class III or IV) heart failure and with N-terminal pro-natriuretic peptide type-B <8500 ng/l. Patients treated with full-dose dexamethasone had similar response rates and survival whether they received bortezomib or not. Intermediate-risk patients who are not fit enough to receive high-dose dexamethasone are likely to take the greatest advantage from the addition of bortezomib to MDex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.